FRISCO, TX / ACCESS Newswire / October 3, 2025 / GameSquare Holdings, Inc. ("GameSquare" or the "Company") a next-generation media, entertainment, technology and digital native treasury company, today announced its initial stock repurchase under its previously announced $5 million authorization. GameSquare repurchased 833,124 shares of its common stock for $599,148, representing an average price of approximately $0.7192.
How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now — Neutral
AM CBOE CGDV CSWC DIVO ELS EME FIX FVR GE ICAP JEPQ KMI KRC LB LHX LLY MO MPLX MSFT NVDA O ODFL OWL PFXF Seeking Alpha — October 03, 2025Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven REITs, natural gas midstream companies, select high-yield stocks, BDCs, preferred equity ETFs, and actively managed income funds.
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results — Neutral
ZBH PRNewsWire — October 03, 2025WARSAW, Ind. , Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m.
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting — Neutral
BCTX GlobeNewsWire — October 03, 2025PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Neutral
KURA GlobeNewsWire — October 03, 2025SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on October 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 122,250 shares of common stock to seven (7) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing …
Applied Materials Stock Falls Along With Lam Research and KLA. China Revenue Is at Risk. — Negative
AMAT KLAC LRCX Barrons — October 03, 2025Applied Materials stock has been on a strong run but new export restrictions threaten its Chinese business.
Exxon Mobil's Future Is Not Priced In Yet, Buy Ahead Of Q3 — Positive
XOM Seeking Alpha — October 03, 2025Exxon Mobil offers 25% upside trading below fair value despite strong fundamentals, new tech, and robust cash flow. XOM's proprietary Permian Basin tech could double recovery rates, unlocking billions in additional revenue and establishing a durable competitive moat. Guyana deepwater project delivers massive, low-cost production growth, with execution ahead of schedule and substantial profit potential for XOM.
J.M. SMUCKER (SJM) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into J.M. — Neutral
SJM GlobeNewsWire — October 03, 2025Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Smucker To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Smucker and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Should First Trust Dow 30 Equal Weight ETF (EDOW) Be on Your Investing Radar? — Neutral
EDOW Zacks Investment Research — October 03, 2025The First Trust Dow 30 Equal Weight ETF (EDOW) was launched on August 8, 2017, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market.
Is First Trust STOXX European Select Dividend ETF (FDD) a Strong ETF Right Now? — Neutral
FDD Zacks Investment Research — October 03, 2025Launched on 08/27/2007, the First Trust STOXX European Select Dividend ETF (FDD) is a smart beta exchange traded fund offering broad exposure to the European Equity ETFs category of the market.
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? — Neutral
PFM Zacks Investment Research — October 03, 2025If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the Invesco Dividend Achievers ETF (PFM), a passively managed exchange traded fund launched on September 15, 2005.
Is Fidelity Quality Factor ETF (FQAL) a Strong ETF Right Now? — Positive
FQAL Zacks Investment Research — October 03, 2025Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Fidelity Quality Factor ETF (FQAL) is a smart beta exchange traded fund launched on 09/12/2016.
Should Invesco S&P MidCap 400 Pure Value ETF (RFV) Be on Your Investing Radar? — Neutral
RFV Zacks Investment Research — October 03, 2025Launched on March 1, 2006, the Invesco S&P MidCap 400 Pure Value ETF (RFV) is a passively managed exchange traded fund designed to provide a broad exposure to the Mid Cap Value segment of the US equity market.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? — Neutral
PBE Zacks Investment Research — October 03, 2025Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Should iShares U.S. Small-Cap Equity Factor ETF (SMLF) Be on Your Investing Radar? — Neutral
SMLF Zacks Investment Research — October 03, 2025The iShares U.S. Small-Cap Equity Factor ETF (SMLF) was launched on April 28, 2015, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Blend segment of the US equity market.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now? — Neutral
PHO Zacks Investment Research — October 03, 2025A smart beta exchange traded fund, the Invesco Water Resources ETF (PHO) debuted on 12/06/2005, and offers broad exposure to the Industrials ETFs category of the market.
Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now? — Neutral
SDY Zacks Investment Research — October 03, 2025Designed to provide broad exposure to the Style Box - Large Cap Value category of the market, the SPDR S&P Dividend ETF (SDY) is a smart beta exchange traded fund launched on 11/08/2005.
Should Vanguard Russell 2000 Value ETF (VTWV) Be on Your Investing Radar? — Neutral
VTWV Zacks Investment Research — October 03, 2025Designed to provide broad exposure to the Small Cap Value segment of the US equity market, the Vanguard Russell 2000 Value ETF (VTWV) is a passively managed exchange traded fund launched on September 22, 2010.
Former Commander of U.S. Central Command General Michael “Erik” Kurilla Joins Lazard as Senior Advisor — Neutral
LAZ Business Wire — October 03, 2025NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ), the preeminent global financial advisory and asset management firm, announced today that Retired Four-Star U.S. Army General and Former Commander of U.S. Central Command Michael “Erik” Kurilla has joined as Senior Advisor in Lazard's Geopolitical Advisory group, effective immediately. General Kurilla brings deep expertise in strategic command within complex environments, most notably in the Middle East and Central Asia. His appointment builds.